In a preclinical mouse model, targeting AR with AR degradation enhancers showed an effectively suppressed RCC progression, indicating a promising therapeutic approach.60 Guan et al. described a further pro-angiogenic effect of AR by demonstrating its function as a regulator of the PI3K/AKT → NF-κB → CXCL5 signalling pathway, which is known to influence RCC progression and endothelial cell recruitment. Here, CXCL5 is linked to renal cell adenocarcinoma.